The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

EXACT Sciences Corp. is a cancer screening and diagnostics ... The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences said it has agreed to buy Thrive for a cash and stock deal worth up to $2.15 billion, positioning it as a leader in the cancer-screening market. The Madison-based company has made ...

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test ...

Stay well-informed and make prudent decisions using our Ratings Table. Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in ...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said ...

The results missed Wall Street expectations. MADISON, Wis., November 05, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced ...